FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293230583> ?p ?o ?g. }

• W4293230583 abstract "<h3> background and importance</h3> In patients with cystic fibrosis (CF), long-term adherence to various treatments is considered low (46%–70%). Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have recently been licensed. Low adherence to these treatments may decrease efficacy. <h3>Aim and objectives</h3> To assess adherence to CFTR modulators and determine if there are differences because of length of treatment. <h3>Material and methods</h3> Retrospective observational study of CF patients under treatment with a CFTR modulator (tezacaftor/ivacaftor; elexacaftor/tezacaftor/ivacaftor; lumacaftor/ivacaftor) dispensed at the outpatient unit of the Children’s Hospital Pharmacy Service, between January 2020 and April 2021. Demographic variables (age and sex), prescription and dispensing dates, and amount dispensed were obtained from the electronic prescription records. Adherence was calculated using the medication possession ratio (MPR). MPR ≥ 80% was considered adequate adherence. Continuous variables were expressed as mean (SD) or median (Q1-Q3), and categorical variables as absolute and relative frequency. A non-parametric test of comparison of proportions was used to assess the relationship between adherence and length of treatment (less or greater than 12 months). Statistical analysis was performed with Stata version 13. <h3>Results</h3> Eighty-two patients (36 women, 43.9%), 67 (81.7%) of whom were adults with a median of 31.2 years (Q1-Q3 = 26.1–39.0) and 15 (18.3%) were children or adolescents with a median of 11.6 years (Q1-Q3 = 7.6–15.6). Treatments dispensed were: tezacaftor/ivacaftor + ivacaftor (61 patients; 74.4%), elexacaftor/tezacaftor/ivacaftor + ivacaftor (13 patients; 15.9%) and lumacaftor/ivacaftor (8 patients; 9.8%). At the time of analysis, 55 patients (67.1%) had been in treatment for less than 12 months and 27 (32.9%) more than 12 months.The mean MPR was 102.7% (SD 11.5%). Eighty-one patients (98.7%) had adequate adherence. The mean MPR in the group lasting less than 12 months was 104.8% (SD 11.7%) and 98.3% (SD 9.7%) in those lasting more than 12 months (p=0.327). <h3>Conclusion and relevance</h3> Adherence to CFTR modulators is higher than observed for other drugs in CF patients, but there is a need to study whether adherence with these drugs is maintained in the long term. Although there were no differences in adherence according to the length of treatment, the only patient considered non-adherent was on treatment greater than 12 months. <h3>References and/or acknowledgements</h3> <h3>Conflict of interest</h3> No conflict of interest" @default.
• W4293230583 created "2022-08-27" @default.
• W4293230583 creator A5017862100 @default.
• W4293230583 creator A5035441705 @default.
• W4293230583 creator A5046648040 @default.
• W4293230583 creator A5046996388 @default.
• W4293230583 creator A5047562227 @default.
• W4293230583 creator A5048541920 @default.
• W4293230583 creator A5071239088 @default.
• W4293230583 creator A5077062849 @default.
• W4293230583 date "2022-03-01" @default.
• W4293230583 modified "2023-09-26" @default.
• W4293230583 title "4CPS-197 Evaluation of adherence to cystic fibrosis transmembrane conductance protein modulator drugs" @default.
• W4293230583 doi "https://doi.org/10.1136/ejhpharm-2022-eahp.198" @default.
• W4293230583 hasPublicationYear "2022" @default.
• W4293230583 type Work @default.
• W4293230583 citedByCount "0" @default.
• W4293230583 crossrefType "proceedings-article" @default.
• W4293230583 hasAuthorship W4293230583A5017862100 @default.
• W4293230583 hasAuthorship W4293230583A5035441705 @default.
• W4293230583 hasAuthorship W4293230583A5046648040 @default.
• W4293230583 hasAuthorship W4293230583A5046996388 @default.
• W4293230583 hasAuthorship W4293230583A5047562227 @default.
• W4293230583 hasAuthorship W4293230583A5048541920 @default.
• W4293230583 hasAuthorship W4293230583A5071239088 @default.
• W4293230583 hasAuthorship W4293230583A5077062849 @default.
• W4293230583 hasBestOaLocation W42932305831 @default.
• W4293230583 hasConcept C126322002 @default.
• W4293230583 hasConcept C2426938 @default.
• W4293230583 hasConcept C2776502428 @default.
• W4293230583 hasConcept C2776938444 @default.
• W4293230583 hasConcept C2778428886 @default.
• W4293230583 hasConcept C3020110884 @default.
• W4293230583 hasConcept C71924100 @default.
• W4293230583 hasConcept C98274493 @default.
• W4293230583 hasConceptScore W4293230583C126322002 @default.
• W4293230583 hasConceptScore W4293230583C2426938 @default.
• W4293230583 hasConceptScore W4293230583C2776502428 @default.
• W4293230583 hasConceptScore W4293230583C2776938444 @default.
• W4293230583 hasConceptScore W4293230583C2778428886 @default.
• W4293230583 hasConceptScore W4293230583C3020110884 @default.
• W4293230583 hasConceptScore W4293230583C71924100 @default.
• W4293230583 hasConceptScore W4293230583C98274493 @default.
• W4293230583 hasLocation W42932305831 @default.
• W4293230583 hasOpenAccess W4293230583 @default.
• W4293230583 hasPrimaryLocation W42932305831 @default.
• W4293230583 hasRelatedWork W1983683260 @default.
• W4293230583 hasRelatedWork W198406279 @default.
• W4293230583 hasRelatedWork W2116885262 @default.
• W4293230583 hasRelatedWork W2128229997 @default.
• W4293230583 hasRelatedWork W3016750854 @default.
• W4293230583 hasRelatedWork W3026310509 @default.
• W4293230583 hasRelatedWork W3207166609 @default.
• W4293230583 hasRelatedWork W4229375806 @default.
• W4293230583 hasRelatedWork W4300716325 @default.
• W4293230583 hasRelatedWork W4300863638 @default.
• W4293230583 isParatext "false" @default.
• W4293230583 isRetracted "false" @default.
• W4293230583 workType "article" @default.